Earnings Call Summary | Collplant(CLGN.US) Q4 2023 Earnings Conference
Earnings Call Summary | Collplant(CLGN.US) Q4 2023 Earnings Conference
The following is a summary of the CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript:
以下是CollPlant Biotechnologies Ltd.（CLGN）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
CollPlant reported Q4 2023 revenues of $299,000, an increase from $58,000 in Q4 2022, primarily from collagen product sales.
Full year 2023 revenues were $11 million, with a substantial contribution from their business partner AbbVie which included a $10 million milestone payment.
Fourth quarter cost of revenues was $773,000 compared to $62,000 in Q4 2022, and the full year cost of revenues for 2023 stood at $2 million, up from $400,000 in 2022.
CollPlant recorded a GAAP net loss for Q4 2023 of $4.7 million or $0.41 per share, compared to a net loss of $4.4 million or $0.39 per share for Q4 2022, and a full-year net loss for 2023 was $7 million or $0.62 per share as against $16.7 million or $1.53 per share in 2022.
The company reported cash and cash equivalents of $26.7 million as of December 31, 2023, sufficient for operational requirements until the end of 2025.
CollPlant報告稱，2023年第四季度收入爲29.9萬美元，高於2022年第四季度的58,000美元，主要來自膠原蛋白產品的銷售。
2023年全年收入爲1100萬美元，其中包括來自其業務合作伙伴艾伯維的巨額捐款，其中包括一筆1000萬美元的里程碑式付款。
第四季度的收入成本爲77.3萬美元，而2022年第四季度爲62,000美元，2023年的全年收入成本爲200萬美元，高於2022年的40萬美元。
CollPlant在2023年第四季度錄得的GAAP淨虧損爲470萬美元，合每股虧損0.41美元，而2022年第四季度的淨虧損爲440萬美元，合每股虧損0.39美元，2023年全年淨虧損爲700萬美元，合每股虧損0.62美元，而2022年爲1,670萬美元，合每股虧損1.53美元。
該公司報告稱，截至2023年12月31日，現金及現金等價物爲2670萬美元，足以滿足2025年底之前的運營需求。
Business Progress:
業務進展：
CollPlant advanced their dermal filler product candidate towards commercialization with AbbVie. This product is currently in its clinical phase of development.
A U.S. patent approval related to photocurable dermal filler product strengthens their foothold in the aesthetics market.
They are also working on a regenerative breast implants product which is in preclinical development and have done large animal studies to optimize design and composition.
The company also initiated a joint development and collaboration agreement with Stratasys for the bioprinting of CollPlant's breast implants.
CollPlant's governance initiatives include joining the United Nations Global Compact and plans to reveal an ESG report for 2023 in Q2 2024.
Future plans include continuation and expansion of collaborations, additional large animal studies for commercial-sized breast implants, and ongoing development of regenerative aesthetic medicine applications leveraging their proprietary rhCollagen and bioink technologies.
CollPlant與艾伯維一起將其候選皮膚填充產品推向商業化。該產品目前處於臨床開發階段。
一項與光固化皮膚填充產品相關的美國專利批准鞏固了他們在美容市場的立足點。
他們還在研究一種再生乳房植入物產品，該產品處於臨床前開發階段，並已進行了大型動物研究以優化設計和成分。
該公司還啓動了與Stratasys的聯合開發和合作協議，對CollPlant的乳房植入物進行生物打印。
CollPlant的治理舉措包括加入聯合國全球契約，並計劃在2024年第二季度公佈2023年的ESG報告。
未來的計劃包括繼續和擴大合作，對商業尺寸的乳房植入物進行更多的大型動物研究，以及利用其專有的rhCollagen和bioink技術持續開發再生美容醫學應用。
More details: Collplant IR
更多詳情： 協同紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。